Get this delivered to your inbox, and more info about our products and services.
Stifel upgrades biotech stock on a narrative shift in Alzheimer’s treatment
Stifel sees Biogen stock rallying nearly 32% from here.
14 words~1 min read
Related reading
This biotech stock could see a sharp swing higher after years of struggling,…
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
This Biogen Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Biogen…
Top Wall Street analysts upgraded Biogen Inc. and Cognizant Technology Solutions, see analyst ratings page for full changes and…
Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug
Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a…
Goldman Sachs says this under-the-radar biotech play could more than double in…
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
Buy this biotech stock on pivot to immune disease treatments, Wells Fargo says
The bank's research arm raised its rating on the stock to overweight from equal weight.
The charts are showing this biotech stock can strengthen into year-end
David Keller breaks down the technicals on this biotech giant.